Companies Dominating the Immunoglobulin (IgG) Replacement Therapy Landscape
- Boehringer Ingelheim
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Grifols, S.A.
- Octapharma AG
- CSL Limited
- BDI Pharma Inc.
- China Biologics Products Inc.
- Abeona Therapeutics
- Baxter International Inc.
- Kedrion Biopharma
- LFB Group
Browse Key Market Insights with Data Illustration:
In the News
- Boehringer Ingelheim declared that it has begun the Phase 1 research (NCT05658107) to evaluate the safety, tolerability, and pharmacokinetics of BI 765423, its first-in-class IL-11 inhibitor antibody, in healthy volunteers. Boehringer Ingelheim is already a world leader in the management of pulmonary fibrosis, and the company's long-term dedication to treating fibrotic disease across therapeutic domains is demonstrated by the start of the anti-IL-11 treatment's clinical development.
- Leading manufacturer of plasma medications, Grifols, has begun selling its 20% subcutaneous immunoglobulin, XEMBIFY®, in Spain. Primary immunodeficiencies (PID) and some secondary immunodeficiencies (SID), the prevalence of which is predicted to rise sharply in the next several years, are the conditions for which this plasma medication is advised.
